Senseonics (NYSE:SENS) will integrate its Eversense continuous glucose monitoring (CGM) system’s real-time glucose data with Companion Medical‘s InPen smart insulin delivery system.

The agreement between Senseonics and Companion, announced today, is slated to bring the technologies together to allow real-time glucose data to be continuously incorporated into the InPen insulin system. This is designed to allow for more relevant insulin dosing information, which could lead to improved diabetes management decisions, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.